| ECRIC |  | WMCIU |  |
---|---|---|---|---|
Total Number of Subjects | 5,694 | Â | 5,468 | Â |
Total time at risk (years) | 31,904 | Â | 25,917 | Â |
Median follow-up (years)* | 5.65 | (0.04 to 8.00)†| 4.85 | (0.07 to 8.00)†|
Number of breast cancer deaths | 737 | Â | 668 | Â |
Number of other deaths | 338 | Â | 287 | Â |
Annual breast cancer mortality rate | 0.023 | (0.021 to 0.025)‡ | 0.026 | (0.024 to 0.028)‡ |
Five-year breast cancer survival rate | 0.89 | (0.88 to 0.90)‡ | 0.88 | (0.87 to 0.89)‡ |
Median age at diagnosis, years | 58 | (23 to 95)†| 58 | (22 to 93)†|
 | Number |  | Number |  |
Age, years | Â | Â | Â | Â |
   <35 | 111 | 2 | 108 | 2 |
   35 to 49 | 1,172 | 21 | 1,195 | 22 |
   50 to 64 | 2,630 | 46 | 2,393 | 44 |
   65 to 74 | 1,124 | 20 | 1,101 | 20 |
   75+ | 657 | 12 | 671 | 12 |
Nodal status | Â | Â | Â | Â |
   0 | 3,532 | 62 | 3,184 | 58 |
   1 | 741 | 13 | 746 | 14 |
   2 to 4 | 806 | 14 | 792 | 14 |
   5 to 9 | 380 | 7 | 451 | 8 |
   10+ | 235 | 4 | 295 | 5 |
Tumour size, mm | Â | Â | Â | Â |
   <10 | 625 | 11 | 485 | 9 |
   10 to 19 | 2,310 | 41 | 2,136 | 39 |
   20 to 29 | 1,627 | 29 | 1,566 | 29 |
   30 to 49 | 845 | 15 | 923 | 17 |
   50+ | 287 | 5 | 358 | 7 |
Grade | Â | Â | Â | Â |
   I | 1,005 | 18 | 1,017 | 19 |
   II | 2,927 | 51 | 2,442 | 45 |
   III | 1,762 | 31 | 2,009 | 37 |
Oestrogen Receptor (ER) Status | Â | Â | Â | Â |
   ER negative | 991 | 17 | 1,116 | 20 |
   ER positive | 4,703 | 83 | 4,352 | 80 |
Adjuvant therapy | Â | Â | Â | Â |
   Chemotherapy | 1,905 | 33 | 2,121 | 39 |
   Endocrine therapy | 4,268 | 75 | 2,406 | 44 |
   Combined chemoendocrine | 1,122 | 20 | 579 | 11 |
Screen detected | Â | Â | Â | Â |
   Yes | 1,621 | 28 | 1,256 | 23 |
   No | 4,073 | 72 | 4,212 | 77 |